On February 21, 2024, the strategic cooperation signing ceremony between 3D Medicines (1244.HK) and Novatim Immune Therapeutics (Zhejiang) Co., Ltd. (hereinafter referred to as "Novatim") was held in Shanghai. Dr. Gong Zhaolong, the chairman and CEO of 3D Medicines, and Dr. Wu Guoxiang, the chairman and CEO of Novatim, signed the strategic cooperation agreement. This cooperation aims to explore the combination of 3D Medicines' Envidra® (Envovalimab) and Novatim's KY-0118. In addition, in the future, the two parties will also discuss further cooperation in multiple aspects such as the rights of Novatim's dual-target CAR-T products and global clinical trial research.
KY-0118 is the first core product independently developed by Novatim, a mutant IL-2 fusion protein targeting PD-1. Its unique design concept has exerted the effect of a next generation agonist, and its research progress in the same field is on par with Roche, ranking among the top globally. The single use of KY-0118 has demonstrated certain effectiveness in clinical trials. When combined with PD-L1 monoclonal antibody, it can increase the tumor suppression rate of KY-0118 alone from 69.2% or that of PD-L1 alone from 65.7% to 100%, achieving complete tumor regression in animal models.
Dr. Wu Guoxiang, the chairman and CEO of Novatim, stated
Enveda® of 3D Medicines is the world's first approved subcutaneous PD-L1 inhibitor. Currently, it is undergoing multi-center and multi-indication clinical trials as a monotherapy and in various combinations worldwide. The collaboration of KY-0118 with Enveda® in combination therapy has demonstrated a result of 1+1>2 both in terms of mechanism and existing experimental data. In the future, it will jointly explore more possibilities for tumor immunotherapy cooperation and accelerate the progress of product launch, achieving complementary advantages.
The strategic cooperation between the two parties has also received strong support from the government of Anji County, Zhejiang Province, where Novatim has been established. In the future, the two parties will fully leverage the main advantages and industry influence of Novatim that have already been established in Anji to make greater contributions to the development of the life and health industry in Anji.
Gong Zhaolong, the chairman and CEO of 3D Medicines, said
Novatim has independently developed a large-molecule drug, KY-0118. This drug has been used alone in clinical trials targeting advanced solid tumors in 8 centers across the country. Preliminary results indicate certain effectiveness. A clinical trial combining KY-0118 with PD-L1 monoclonal antibody is also about to be conducted simultaneously worldwide. This collaboration with Novatim on the KY-0118 combination is a very promising opportunity. It represents an initial exploration of deepening strategic cooperation between the two parties and also helps accelerate the market launch of Envidar® for new indications.
Novatim has a strong ability in independent research and product innovation. Shididi Medicine has rich experience in drug development. The two parties will carry out multi-faceted cooperation in areas such as global product rights cooperation and global clinical research, to accelerate the exploration of better tumor immunotherapy solutions and help cancer patients live longer and better.
Regarding 3D Medicines Inc.
3D Medicines Inc. is an innovative pharmaceutical company that has entered the commercialization stage and focuses on the field of tumor treatment. With the vision of "helping cancer patients live longer and better", the company develops anti-tumor drugs in response to the trend of chronicization in tumor treatment. On December 15, 2022, the company officially listed on the main board of the Hong Kong Stock Exchange, with the stock abbreviation: 3D Medicines and the stock code: 1244.
The company's product line includes 12 innovative drugs with clinical value. Among them, 8 have entered the clinical development or commercialization stage. The new drug Envida, a subcutaneous injection of PD-L1 single-domain antibody, has been approved for marketing by the National Medical Products Administration. The company's over 200-person international team has extensive experience in drug discovery, preclinical research, clinical development, application for marketing approval, and commercialization. Multiple indications have received orphan drug designation or priority review from the FDA and NMPA. 3D Medicines adheres to the patient-centered principle and provides more treatment options for global cancer patients.
For more information, please visit: http://www.3d-medicines.com
Regarding Novatim
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. was established in 2018. It is a biopharmaceutical technology enterprise specializing in the research and clinical application of innovative drugs for tumor immunotherapy. The company, based on clinical needs and its focus on tumor immunotherapy, has established research platforms such as the dual-function antibody platform, the nano-bispecific ADC platform, and the enhanced dual-target CAR-T platform. Through breakthroughs at the level of key technologies, it has developed nearly 10 FIC/BIC products.
The first core product independently developed by Novatim from the source, the targeted PD-1 mutant IL-2 fusion protein - KY-0118 injection, features a unique design concept that enables the function of a new generation of agonists. It is a new type of targeted IL-2 product that specifically activates CD8+ T cells. It is known that in the same field, the research progress of this product is on par with Roche and is at the forefront of the first tier. Currently, clinical trials are being conducted at the General Hospital of the People's Liberation Army as the central unit. The preliminary clinical trial data have demonstrated good safety and significant effectiveness.
